$58.5 Million is the total value of Alerce Investment Management, L.P.'s 6 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AKBA | AKEBIA THERAPEUTICS INC | $18,473,836 | +24.6% | 16,205,119 | 0.0% | 31.57% | +63.7% | |
ANNX | ANNEXON INC | $16,652,217 | -33.0% | 7,056,024 | 0.0% | 28.46% | -11.9% | |
AMWL | AMERICAN WELL CORPcl a | $12,256,589 | -44.3% | 10,475,717 | 0.0% | 20.95% | -26.8% | |
AADI BIOSCIENCE INC | $7,893,217 | -29.2% | 1,630,830 | 0.0% | 13.49% | -7.0% | ||
ASMB | ASSEMBLY BIOSCIENCES INC | $1,971,338 | -23.0% | 2,227,500 | 0.0% | 3.37% | +1.1% | |
AILERON THERAPEUTICS INC | $1,262,308 | -15.1% | 830,466 | 0.0% | 2.16% | +11.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMERICAN WELL CORP | 12 | Q3 2023 | 62.9% |
ANNEXON INC | 12 | Q3 2023 | 35.9% |
AKEBIA THERAPEUTICS INC | 12 | Q3 2023 | 31.6% |
ASSEMBLY BIOSCIENCES INC | 12 | Q3 2023 | 8.7% |
AADI BIOSCIENCES INC | 9 | Q3 2023 | 24.1% |
AILERON THERAPEUTICS INC | 8 | Q3 2022 | 14.4% |
GLOBAL BLOOD THERAPEUTICS IN | 8 | Q3 2022 | 23.4% |
AILERON THERAPEUTICS INC | 4 | Q3 2023 | 2.3% |
AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 5.2% |
View Alerce Investment Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-04 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-09 |
13F-HR | 2021-11-15 |
View Alerce Investment Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.